Horizons in Endometriosis: Proceedings of the Montreux Reproductive Summit, 14-15 July 2023

Alexandre Vallée, A Vallée, E Saridogan, F Petraglia, Felice Petraglia, J Keckstein, N Polyzos, Nikolaos P. Polyzos, Christine Wyns, C Wyns, L Gianaroli, Luca Gianaroli, B Tarlatzis, Basil C. Tarlatzis, J M Ayoubi, Anis Féki, A Feki, Montreux Reproductive Summit Working Group
Facts, views & vision in ObGyn · 2024 · vol. 16(Supplement 1) , pp. 1–32 · doi:10.52054/fvvo.16.s1.011 · PMID:38603778 · W4394763031
article OA: diamond CC0 ⤵ 5 in-corpus citations
🔓 Open OA copy Full text JSON View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by claude@2026-06, 2026-06-07 ⓘ

This Montreux summit proceedings summarize discussions on future directions for endometriosis classification, diagnosis, prevention, fertility preservation, novel therapies, and hormonal substitution post-treatment.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

⚙ AI-generated deep summary by claude@2026-06, 2026-06-07 · read from full text ⓘ

This article is the proceedings of the Montreux Reproductive Summit held on 14–15 July 2023, published in April 2024 as an original article in Facts Views Vis ObGyn. The text provided includes bibliographic and publication metadata, but it does not include the proceedings’ substantive content (e.g., study descriptions, methods, or findings). The only explicit limitation available from the provided material is that the article is only accessible via PDF and the current paper body contains no summaryable research results. This paper is centrally about endometriosis — it is titled as endometriosis-focused proceedings and is published in an endometriosis section/journal context, though the specific reported content is not present in the supplied text.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Abstract

Endometriosis is a complex and chronic gynaecological disorder that affects millions of women worldwide, leading to significant morbidity and impacting reproductive health. This condition affects up to 10% of women of reproductive age and is characterised by the presence of endometrial-like tissue outside the uterus, potentially leading to symptoms such as chronic pelvic pain, dysmenorrhoea, dyspareunia, and infertility. The Montreux summit brought a number of experts in this field together to provide a platform for discussion and exchange of ideas. These proceedings summarise the six main topics that were discussed at this summit to shed light on future directions of endometriosis classification, diagnosis, and therapeutical management. The first question addressed the possibility of preventing endometriosis in the future by identifying risk factors, genetic predispositions, and further understanding of the pathophysiology of the condition to develop targeted interventions. The clinical presentation of endometriosis is varied, and the correlation between symptoms severity and disease extent is unclear. While there is currently no universally accepted optimal classification system for endometriosis, several attempts striving towards its optimisation - each with its own advantages and limitations - were discussed. The ideal classification should be able to reconcile disease status based on the various diagnostic tools, and prognosis to guide proper patient tailored management. Regarding diagnosis, we focused on future tools and critically discussed emerging approaches aimed at reducing diagnostic delay. Preserving fertility in endometriosis patients was another debatable aspect of management that was reviewed. Moreover, besides current treatment modalities, potential novel medical therapies that can target underlying mechanisms, provide effective symptom relief, and minimise side effects in endometriotic patients were considered, including hormonal therapies, immunomodulation, and regenerative medicine. Finally, the question of hormonal substitution therapy after radical treatment for endometriosis was debated, weighing the benefits of hormone replacement.
Full text 904 characters · extracted from oa-html · click to expand
European Society for Gynaecological Endoscopy E-ISSN: 2684-4230 ISSN: 2032-0418 About Us Journal Policies Free-of-Charge Publication Copyright & Open Access Policy Digital Archiving & Preservation Policy Peer Review Policy Clinical Trial Policy The Role of the Editorial Board Editorial Board Instructions Instructions to Authors Information For Reviewers Ethics Contact Us Horizons in Endometriosis: Proceedings of the Montreux Reproductive Summit, 14-15 July 2023 PDF Cite Share Request Original Article VOLUME: 16 ISSUE: 1 P: 1 - 32 April 2024 Horizons in Endometriosis: Proceedings of the Montreux Reproductive Summit, 14-15 July 2023 Facts Views Vis ObGyn 2024;16(1):1-32 DOI: 10.52054/FVVO.16.s1.011 Copyright & Licence Information Galenos & Facts Views Vis ObGyn Disclaimer No information available. No information available PDF Cite Share Request Article is only available in PDF format. Show PDF

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

⚙ Ask this paper AI returns verbatim quotes from the full text · source: oa-html ⓘ

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Condition tags

endometriosischronic_pelvic_paindysmenorrheadyspareuniainfertility

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (100)

Cited by (5)

Source provenance

europepmc
last seen: 2026-06-04T01:30:01.192114+00:00
openalex
last seen: 2026-06-04T00:00:01.174412+00:00
pubmed
last seen: 2026-06-01T00:32:48.163402+00:00
License: CC0 · commercial use OK